Does comprehensive measurement of endometrial immune cells predict the clinical outcomes in women undergoing euploid embryo transfer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500099995

Enrollment

Unknown

Registered

2025-04-01

Start date

2025-05-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Implantation failure

Interventions

Ongoing pregnancy group:None

Non-conception group:None

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Women undergoing PGT because of single gene disorders, chromosomal abnormalities, carrier of inherited genetic diseases, advanced female age, repeated implantation failure, recurrent miscarriage; 2. Day 2 follicle-stimulating hormone (FSH) levels of 30 nmol/L.

Exclusion criteria

Exclusion criteria: 1. Acute/Chronic endometritis; 2. Endometriosis; 3. Infectious diseases; 4. Application of antibiotics within 3 months; 5. Structural uterine abnormalities; 6. Antiphospholipid syndrome; 7. Endocrine or metabolic disorders; 8. Autoimmune disease; 9. Undergoing immunotherapy; 10. Cancer or post-cancer status; 11. Significant medical complications; 12. Previous enrolment to study or current enrolment to other studies; 13. Smoking; 14. Obesity; 15. Antihypertensive or vascular constricting medications; 16. Muscular constricting agents.

Design outcomes

Primary

Measure	Time frame
Percentages of uNK cell subsets;	—

Secondary

Measure	Time frame
Percentages of macrophage subsets in endometrium;Percentages of T cell subsets in endometrium;	—

Countries

China

Contacts

Public ContactTao Zhang

Prince of Wales Hospital, The Chinese University of Hong Kong

taozhang@cuhk.edu.hk+86 182 1920 8402

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026